A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in Plasmodium vivax Hypnozoites

Steven P. Maher, Malina A. Bakowski, Amélie Vantaux, Erika L. Flannery, Chiara Andolina, Manoj Kumar Gupta, Yevgeniya Antonova‐Koch, M. Argomaniz, Monica Cabrera-Mora, Brice Campo, A. T. Chao, Arnab K. Chatterjee, Wenjie Cheng, E. Chuenchob, Caitlin Cooper, Karissa E. Cottier, Mary R. Galinski, Anke Harupa-Chung, Hye Young Ji, Sean B. Joseph, Thomas Lenz, Stefano Lonardi, J. Matheson, Sebastian A. Mikolajczak, T. Moeller, A Orban, Vivian Padín-Irizarry, K. Pan, Julie Péneau, Jacques Prudhomme, Camille Roesch, Anthony A. Ruberto, Svapna Sabnis, Celia L. Saney, Jetsumon Sattabongkot, Saleh Sereshki, Sangrawee Suriyakan, Ratawan Ubalee, Yin Wang, Praphan Wasisakun, Junqi Yin, Jean Popovici, Case W. McNamara, Chester J. Joyner, François Nosten, Benoît Witkowski, Karine G. Le Roch, Dennis E. KylebioRxiv 2023 · DOI

TL;DR

This study tackles the challenge of Plasmodium vivax malaria by identifying new drug targets and repurposing existing drugs to eliminate dormant liver-stage parasites (hypnozoites). By screening epigenetic inhibitors, the researchers found that targeting DNA methylation and histone modifications shows promise for developing novel radical cure treatments.

What Problem Does This Paper Address?

Plasmodium vivax malaria is a significant global health burden, characterized by its ability to cause relapsing infections due to dormant liver-stage parasites called hypnozoites. Current FDA-approved treatments for radical cure (eliminating hypnozoites) have limitations, including contraindications for certain populations and potential resistance issues. This paper aims to address this by identifying new drug targets and repurposing existing drugs that can effectively eliminate these quiescent hypnozoites, thereby improving malaria treatment and potentially eradication efforts.

Methods

The researchers employed a multi-pronged approach:

  • Drug Repurposing Screen: They utilized the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library, a collection of ~12,000 developmental, approved, and discontinued drugs.
  • Epigenetic Inhibitor Screen: A dedicated library of epigenetic inhibitors was screened to specifically target pathways involved in hypnozoite biology.
  • In Vitro Liver Stage Assay: A robust 8-day P. vivax liver stage assay using primary human hepatocytes (PHH) was developed and adapted for high-throughput screening. This assay allowed for the maturation of hypnozoites before drug treatment.
  • Immunofluorescence Microscopy: Used to visualize and quantify DNA methylation (5-methylcytosine, 5mC) and hydroxymethylation (5hmC) in Plasmodium liver forms.
  • Bisulfite Sequencing: Employed to map genomic DNA methylation at single-nucleotide resolution in sporozoites.
  • Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS/MS): Used to quantify 5mC, 5hmC, and 2'-deoxyguanosine (dG) in genomic DNA.
  • Drug Combination Studies: Assessed potential synergistic effects between identified hits and known epigenetic modulators.
  • Pharmacokinetic Studies: Evaluated the in vivo behavior of promising drug candidates in nonhuman primates.

Datasets

  • ReFRAME Library: Approximately 12,823 compounds were screened.
  • Epigenetic Inhibitor Library: A library of 773 compounds targeting various epigenetic pathways.
  • Plasmodium vivax and Plasmodium cynomolgi: Genomic DNA from sporozoites and liver stages were used for methylation analysis.
  • Human Hepatocytes (PHH) and Simian Hepatocytes (PSH): Primary cells were used for in vitro assays.
  • Rhesus Macaque Pharmacokinetic Data: Data from oral dosing studies.

Key Insights and Ideas

  • Epigenetics as a Key Regulator of Hypnozoite Quiescence: The study strongly suggests that epigenetic mechanisms, particularly DNA methylation and histone modifications, play a crucial role in the formation and persistence of P. vivax hypnozoites.
  • Drug Repurposing for Radical Cure: The ReFRAME library screen successfully identified existing drugs with activity against hypnozoites, offering a faster path to potential new treatments.
  • Species-Specific Differences: While some hits were effective against P. vivax, they showed varying activity against P. cynomolgi, highlighting potential species-specific differences in hypnozoite biology and drug targets. This also challenges the direct translation of findings from P. cynomolgi models to P. vivax.
  • DNA Methylation in Liver Stages: The presence of 5mC in P. vivax liver stages and sporozoites, and its potential correlation with gene expression, opens new avenues for understanding parasite development and control.
  • Synergy with DNMT Inhibitors: The combination of cadralazine with a DNA methyltransferase inhibitor (5-azacytidine) demonstrated synergistic activity, suggesting a multi-target approach could be beneficial.

Key Results

  • Identification of Novel Hypnozonticidal Hits: The screens identified several classes of epigenetic inhibitors, including DNA methyltransferase (DNMT) inhibitors and histone modification inhibitors, that were selectively active against P. vivax and P. cynomolgi hypnozoites.
  • Hydralazine Analogs Show Potency: Cadralazine, a hydralazine analog, demonstrated significant potency and selectivity against P. vivax hypnozoites.
  • DNA Methylation is Present: Immunofluorescence and bisulfite sequencing confirmed the presence of 5-methylcytosine (5mC) in P. vivax and P. cynomolgi liver stages and sporozoites.
  • Potential Link Between Methylation and Gene Expression: Methylation levels in promoter regions and first exons showed an inverse relationship with mRNA abundance in P. vivax sporozoites, suggesting a role in gene regulation.
  • MMV019721 as a Potential Target: An acetyl-CoA synthetase inhibitor, MMV019721, was found to selectively kill P. vivax hypnozoites, implicating acetyl-CoA synthetase as a potential drug target.

Limitations and Future Work

  • Species-Specific Differences: The varying activity of hits against P. vivax and P. cynomolgi hypnozoites suggests that the P. cynomolgi model may not fully recapitulate P. vivax biology, necessitating further development of P. vivax-specific animal models.
  • Host vs. Parasite Targets: While some hits showed selectivity, further studies are needed to definitively determine whether they act on parasite-specific targets or host pathways that influence parasite survival.
  • Technical Limitations: The authors acknowledge that molecular techniques for confirming direct interaction of drugs with targets in P. vivax are still underdeveloped.
  • Future Directions: The authors suggest developing P. vivax transgenic lines for more precise hypnozoite studies, combining epigenetic modulators with other antimalarials, and utilizing single-cell technologies to refine understanding of epigenetic pathways.

Summary updated

Abstract

Radical cure of <i>Plasmodium vivax</i> malaria must include elimination of quiescent 'hypnozoite' forms in the liver; however, the only FDA-approved treatments are contraindicated in many vulnerable populations. To identify new drugs and drug targets for hypnozoites, we screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library and a collection of epigenetic inhibitors against <i>P. vivax</i> liver stages. From both libraries, we identified inhibitors targeting epigenetics pathways as selectively active against <i>P. vivax</i> and <i>P. cynomolgi</i> hypnozoites. These include DNA methyltransferase (DNMT) inhibitors as well as several inhibitors targeting histone post-translational modifications. Immunofluorescence staining of <i>Plasmodium</i> liver forms showed strong nuclear 5-methylcystosine signal, indicating liver stage parasite DNA is methylated. Using bisulfite sequencing, we mapped genomic DNA methylation in sporozoites, revealing DNA methylation signals in most coding genes. We also demonstrated that methylation level in proximal promoter regions as well as in the first exon of the genes may affect, at least partially, gene expression in <i>P. vivax</i>. The importance of selective inhibitors targeting epigenetic features on hypnozoites was validated using MMV019721, an acetyl-CoA synthetase inhibitor that affects histone acetylation and was previously reported as active against <i>P. falciparum</i> blood stages. In summary, our data indicate that several epigenetic mechanisms are likely modulating hypnozoite formation or persistence and provide an avenue for the discovery and development of improved radical cure antimalarials.
BibTeX
@misc{maher2023drug,
  author = {Steven P. Maher and Malina A. Bakowski and Amélie Vantaux and Erika L. Flannery and Chiara Andolina and Manoj Kumar Gupta and Yevgeniya Antonova‐Koch and M. Argomaniz and Monica Cabrera-Mora and Brice Campo and A. T. Chao and Arnab K. Chatterjee and Wenjie Cheng and E. Chuenchob and Caitlin Cooper and Karissa E. Cottier and Mary R. Galinski and Anke Harupa-Chung and Hye Young Ji and Sean B. Joseph and Thomas Lenz and Stefano Lonardi and J. Matheson and Sebastian A. Mikolajczak and T. Moeller and A Orban and Vivian Padín-Irizarry and K. Pan and Julie Péneau and Jacques Prudhomme and Camille Roesch and Anthony A. Ruberto and Svapna Sabnis and Celia L. Saney and Jetsumon Sattabongkot and Saleh Sereshki and Sangrawee Suriyakan and Ratawan Ubalee and Yin Wang and Praphan Wasisakun and Junqi Yin and Jean Popovici and Case W. McNamara and Chester J. Joyner and François Nosten and Benoît Witkowski and Karine G. Le Roch and Dennis E. Kyle},
  title = {{A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in <i>Plasmodium vivax</i> Hypnozoites}},
  year = {2023},
  doi = {10.1101/2023.01.31.526483},
  howpublished = {bioRxiv},
}
Figure